Large Cancer Panel Test
About This Opportunity
This is a supplies contract in the governance and public administration sector. Located in Finland, Europe, this opportunity is open to firms and consortiums. Proposals must be submitted before September 14, 2026.
Published through Hilma Finland, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the governance and public administration sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. Interested parties should review the full documentation on the original source before submitting their proposal.
Description
The HUS Group (also "the contracting entity", "the Client" or “HUS”) requests tenders for a large cancer panel test for HUS Diagnostic Center. The procurement includes also data analysis software for reporting clinically significant variants, copy number alterations and gene fusions. The software can be offered by the same provider as the large cancer panel test or from a partner company (offer as a group or appeal to a subcontractor's resources), but it needs to be included in the same tender. The software will be procured for the entire lifecycle of the assay.
The procurement consist of gene panels and reagents (also "products") and data analysis software (also "services", e.g. information system provided as Software as a Service).
Laboratory of Genetics at HUS (Helsinki University Hospital) Diagnostic Center is an SFS-EN ISO 15189:2022 accredited laboratory providing diagnostic genetic testing services to all patients at Helsinki and Uusimaa Hospital District. The laboratory operates as a health institution capable of validating in-house developed tests as required by the CE-IVD regulation.
The services include analysis of both constitutional samples and malignancies. The laboratory provides sequencing services mainly using local sequencing capacity (Illumina NovaSeq 6000, NovaSeq X Plus, Ion GeneStudio S5 Prime equipment). The large cancer panel test is intended for detection of small nucleotide variants (SNVs), indels, gene fusions, copy number variations (CNVs), microsatellite instability (MSI), homologous recombination deficiency (HRD), and tumor mutation burden (TMB) relevant for the genetic profiling of solid tumor samples and/or hematological malignancies as well as plasma samples for cfDNA analysis.
Sequencing of the samples is carried out using Illumina NovaSeq sequencers (Illumina NovaSeq 6000 and NovaSeq X Plus). The number of cancer panel tests performed annually is estimated to be between 2500-3000.
The procurement is divided into LOT A and LOT B:
LOT A
- This lot includes gene panel solutions for in-house NGS testing of solid tumors and hematological malignancies, including library preparation reagents, target enrichment reagents defining the panel content, panel-specific reagents, data analysis software, and instructions for use. Sequencing reagents, flow cells, sequencing instruments, and testing services are not included in this procurement.
- This test is based on analysis of total nucleic acids (RNA and/or DNA) extracted from paraffin embedded specimens and/or fresh-frozen specimens
- This lot includes an option for special gene panel and reagents for salivary gland tumors with data analysis software
- This lot includes an an option for a custom gene panel and reagents with data analysis software
- The HUS Group will decide separately on the use of the options
LOT B
- This lot includes gene panel solutions for in-house NGS testing of cell-free DNA, including library preparation reagents, target enrichment reagents defining the panel content, panel-specific reagents, data analysis software, and instructions for use. Sequencing reagents, flow cells, sequencing instruments, and testing services are not included in this procurement
- This test is based on analysis of cell-free DNA from plasma samples
NOTE: For LOT A, the tenderer may offer a catalog panel, a combination of catalog panels, or a custom solution to meet the DNA and RNA requirements. For hematological malignancies, only a panel for DNA is requested. Panel for salivary gland tumors and custom panel are requested as an option.
NOTE: FOR LOT A and LOT B, the tender needs to include all the reagents required to perform the assay, including library preparation reagents, indexing adapters and target enrichment reagents (or equivalent). Nucleic acid extraction reagents, library quantification reagents and sequencer reagents are excluded from the tender.
The subject of the procurement and its requirements are described in more detail in the call for tender and its appendices.
The tenderer can submit a tender to either one or both of the LOTS A and LOT B. The tenderer can be awarded the contract to either one or both tendered lots. The contrcting entity selects one (1) supplier for each lot and will enter into an agreement with the winning supplier.
The estimated start for the contract period is autumn-winter 2026.
The contracting entity recieves a right to test use tendered panels and softwares after the deadline for receiving the tenders.
The procurement volumes presented in the call for tenders are estimates, and the contract does not constitute a mandatory purchase obligation for the contrcting entity or an exclusive right for the supplier to provide the product., LOT A: Panels for Solid Tumors and Hematological Malignancies with Data Analysis Software The subject of the procurement and its requirements are described in more detail in the call for tender and its appendices., LOT B: CfDNA Panel Test with Data Analysis Software The subject of the procurement and its requirements are described in more detail in the call for tender and its appendices.,
Lot 1: LOT A: Panels for Solid Tumors and Hematological Malignancies with Data Analysis Software
The subject of the procurement and its requirements are described in more detail in the call for tender and its appendices.
Lot 2: LOT B: CfDNA Panel Test with Data Analysis Software
The subject of the procurement and its requirements are described in more detail in the call for tender and its appendices.
CPV: 33000000 48000000 72000000
Organisation: HUS Group
Procedure: open
Documents: https://tarjouspalvelu.fi/huslogistiikka?id=572070&tpk=f846dc2e-2626-4867-91e2-dff2eb40c0eb
Data provenance
This notice is sourced from Hilma Finland and was originally published on June 28, 2026. Last refreshed today. BidsFactory mirrors official procurement notices and links back to the source for full legal text.
About HUS Group
HUS Group has issued 27 procurement notices on BidsFactory, including 11 currently open and 8 awarded contracts. Activity concentrates in Health & Medical, Governance & Public Administration, and Information & Communication Technology. All notices are published for Finland. Notices are distributed via Hilma Finland and TED - Tenders Electronic Daily (EU). Most recent publication: June 29, 2026.
Frequently asked questions about this tender
What type of contract is this?
This is a Supplies contract in the Governance & Public Administration sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.
Where will the contract be performed?
The contract is for delivery in Finland. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.
How can I submit a bid?
Visit Hilma Finland to access the full notice, required documents, and submission instructions provided by the contracting authority.
When does this tender close?
The submission deadline is September 14, 2026. You have 76 days left to prepare and submit your proposal to the contracting authority.
Who is the contracting authority?
This notice was issued by HUS Group in Finland. The authority is responsible for evaluating bids, awarding the contract, and managing performance.
Find tenders like this automatically
Set up alerts and filters that match your business — never miss a relevant opportunity again.